Myo‐inositol vs D‐chiro‐inositol
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
52 questions · 52 findings · 3 reviews
No studies found 10 · 19.2%GRADE not reported 19 · 36.5%Very low 17 · 32.7%Low 6 · 11.5%Moderate 0 · 0%High 0 · 0%
Myo‐inositol vs metformin
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs metformin
Adverse events · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs metformin
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
- OR 1.91 [0.81, 4.49]1 study · 120 participantsVery low
Myo‐inositol vs metformin
Ovulation · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
- OR 1.86 [0.89, 3.87]1 study · 120 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
- OR 0.4 [0.19, 0.86]4 studies · 535 participantsVery low
Myo‐inositol vs clomiphene
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 1.27 [0.48, 3.4]1 study · 75 participantsVery low
Myo‐inositol vs clomiphene
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs clomiphene
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 0.21 [0.01, 4.43]1 study · 75 participantsVery low
Myo‐inositol vs clomiphene
Clinical pregnancy · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs clomiphene
Ovulation rate · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation rate compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
- OR 0.59 [0.2, 1.68]1 study · 75 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).
1 finding from 1 review
- OR 1.04 [0.63, 1.71]2 studies · 425 participantsLow
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
- OR 1.27 [0.87, 1.85]4 studies · 535 participantsVery low
Myo‐inositol vs Placebo, no intervention or usual care (with or without placebo)
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs antioxidant (melatonin)
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Myo‐inositol vs antioxidant (melatonin)
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
- OR 0.7 [0.22, 2.24]1 study · 358 participantsVery low
Myo‐inositol vs antioxidant (melatonin)
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
- OR 0.95 [0.57, 1.59]1 study · 358 participantsVery low
Myo‐inositol vs antioxidant (melatonin)
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
- OR 0.83 [0.53, 1.28]1 study · 358 participantsVery low
Intervention not reported
Gestational diabetes mellitus · pregnant women (women with pre‐existing type 1 or type 2 diabetes are NOT included)
It is very uncertain whether the intervention changes gestational diabetes mellitus (very low certainty).
1 finding from 1 review
- Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes 2023 · Cochrane Headline outcomes onlyRR 0.53 [0.31, 0.9]6 studies · 1140 participantsVery low
Intervention not reported
Composite of serious neonatal outcomes · infants of pregnant women
1 finding from 1 review
- Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes 2023 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported